ADHD medicines eased menopause brain fog in women's own ratings, review finds
By Vikram JoshiLife Balance Correspondent, Peepals Shakti
Representative image: This_is_Engineering / Pixabay
A review presented on October 20, 2026, found ADHD drugs improved midlife women's self-rated focus but not objective memory tests; experts call it too early.
What Happened
ADHD medicines may ease the self-reported "brain fog" some women experience around menopause, but they did little on objective memory and attention tests, according to a scoping review presented at The Menopause Society's 2026 Annual Meeting in San Diego, which ran from October 20 to 24, 2026. The findings were reported on October 20. The review, by Tat and colleagues, pooled five small studies and has not yet been published in a peer-reviewed journal, and experts said it is too early to recommend these drugs for this purpose.
Key Facts
- Event: The Menopause Society 2026 Annual Meeting, San Diego, October 20 to 24, 2026; findings reported on October 20.
- What was studied: a scoping review of five studies on two ADHD medicines, lisdexamfetamine (sold as Vyvanse) and atomoxetine (sold as Strattera).
- Who was studied: women aged 45 to 60 whose last menstrual period was less than 10 years earlier.
- Main result: on the Brown Attention Deficit Disorder Scale (BADDS), a questionnaire on attention and organisation problems, lisdexamfetamine lowered scores from 35.7 to 21.2 and atomoxetine from 38.6 to 25.5, compared with placebo.
- Limit: neither drug changed objective measures such as working memory or sustained attention.
- Status: not yet peer-reviewed; the authors cite small samples and reliance on subjective, backward-looking measures as key weaknesses.
- There is no medicine approved by the US Food and Drug Administration for menopausal brain fog.
Why It Matters
"Brain fog" is the everyday name many women give to trouble concentrating, losing a train of thought or forgetting words during the menopause transition. It is not a formal diagnosis, but it is one of the symptoms women most often say affects their working lives. For a woman in her late forties or fifties who manages a team, runs a business or sits in exams for a promotion, feeling that her mind is slower can shake her confidence, even when nothing is wrong with her memory on paper.
That gap between feeling and measurement is exactly what this review found. The two medicines, both used to treat attention deficit hyperactivity disorder (ADHD), improved how women rated their own executive function, the set of skills used to plan, organise, focus and switch between tasks. The questionnaire scores fell by a large margin compared with placebo. Yet when the same women were given objective tests of working memory and sustained attention, the medicines made little or no difference.
That pattern can be read in two ways. It may mean the drugs help women cope better with daily demands in ways a lab test does not capture. Or it may mean that people who know they are on an active drug simply report feeling better. With only five small studies, the review cannot settle which is true, and the authors themselves flag the small sample sizes and the use of subjective, retrospective measures as limits.
The society's own commentary was cautious. Stephanie Faubion, quoted in coverage of the meeting, said brain fog at menopause is usually temporary and does not lead to lasting cognitive decline or dementia. She described studies like this one as useful for finding more options for symptoms, not as a basis for changing treatment now. Coverage of the review also noted that no medicine has been approved by the US Food and Drug Administration for this symptom.
| | Medicine | Self-reported score before | Score after, vs placebo | Objective tests | |
|---|---|---|---|
| | Lisdexamfetamine | 35.7 | 21.2 | Little or no change | |
| | Atomoxetine | 38.6 | 25.5 | Little or no change | |
Impact
Short-term: Nothing changes in treatment. The review is preliminary and unpublished, and the researchers and experts quoted on it say it is too early to recommend ADHD medicines for menopausal brain fog. For now, the work is a signal for researchers rather than a change in what doctors offer.
Long-term: The findings point to the need for larger, well-designed trials that measure both how women feel and how they perform on objective tests. They also add to growing attention on how menopause affects women at work, where midlife is often the peak of a career.
Who is affected: Women in perimenopause and early menopause, especially those in demanding jobs; doctors and gynaecologists who are asked about brain fog; employers building menopause support at work; and researchers designing future trials.
Key Takeaway
A review of five small studies presented on October 20, 2026, found ADHD medicines improved how midlife women rated their own focus but not their measured memory or attention, and experts say it is too early to use them for menopausal brain fog.
Questions and Answers
Do ADHD medications help with menopause brain fog?
A scoping review presented at The Menopause Society's 2026 meeting found that lisdexamfetamine and atomoxetine improved women's self-reported focus and organisation, but not objective tests of working memory or attention. The review covers only five small studies, is not yet peer-reviewed, and experts say it is too early to recommend the drugs for this use.
What is menopausal brain fog?
It is an informal term for trouble concentrating, forgetfulness and slower thinking that some women notice during the menopause transition. Experts quoted on the review said it is usually temporary and does not lead to lasting cognitive decline or dementia.
Is any medicine approved for menopausal brain fog?
No. There is no medicine approved by the US Food and Drug Administration specifically for brain fog linked to menopause, which is why researchers are studying possible options.
What are the limits of the ADHD medicine review?
It pooled only five small studies, relied mostly on women's own retrospective ratings rather than objective tests, and has not been published in a peer-reviewed journal. The authors named small sample sizes and subjective measures as key weaknesses.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
By Vikram Joshi, Life Balance CorrespondentCovers Life Balance and more for Peepals Shakti. All stories by Vikram Joshi
Vikram Joshi is a pen name of the Peepals Global Editorial Team, which researches, fact-checks and publishes every story. The portrait is an illustration.
